Fortis Healthcare is organizing the Fortis Cancer Summit 2026 in New Delhi to discuss the future of global cancer care.
The gathering marks a shift toward holistic treatment models. By focusing on patient-centered care and long-term survivorship, the summit aims to move the medical community beyond traditional survival statistics toward improving the overall quality of life for patients.
The event is a two-day conference [1] themed “Beyond Evidence, Based Oncology.” This theme emphasizes a move toward innovation and a more personalized approach to treatment. The summit brings together a diverse group of professionals, including oncologists, scientists, investors, and patient-advocacy leaders [2].
Collaboration is a central pillar of the event. Organizers intend to promote global cooperation to accelerate the development of new treatments and delivery methods. The goal is to create a united front that integrates cutting-edge research with practical, patient-centric applications, organizers said [2].
Representation at the summit is global, with experts attending from more than 25 countries [3]. This international scale is designed to facilitate the exchange of data and strategies across different healthcare systems, an effort to standardize high-quality care regardless of geography.
Participants will explore how to improve long-term survivorship outcomes [4]. The discussions focus on the evolving nature of oncology, specifically how to balance evidence-based medicine with the unique needs of the individual patient [4].
“The summit brings together a diverse group of professionals, including oncologists, scientists, investors, and patient-advocacy leaders.”
The focus on 'Beyond Evidence-Based Oncology' suggests a transition in the medical field from a strict reliance on generalized clinical trial data to a more nuanced, personalized medicine approach. By involving investors and patient advocates alongside scientists, Fortis is signaling that the future of cancer care depends as much on financial scalability and patient experience as it does on biological breakthroughs.
